Navigation Links
Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
Date:3/31/2009

GENEVA, Switzerland, March 31 /PRNewswire/ -- Viroblock SA has announced today that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by altering and destabilizing cholesterol-rich viral envelopes.

The two pre-clinical studies exposed ferrets to Influenza A Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were conducted by Retroscreen Virology Ltd, a recognized leader in the research and testing of antiviral compounds and vaccines. Both the direct inoculation and the natural transmission protocols have confirmed the effectiveness and the value of the antiviral nasal spray.

These in-vivo campaigns confirm all in laboratory in-vitro studies to date and demonstrate that VCCD Tech represents a breakthrough for inactivating a number of enveloped viruses and their strains.

"Our depletion technology shows no toxicity at the dosage we tested thus far and allegedly limits the development of any viral resistance, and makes it effective on all families of enveloped viruses, such as human and avian influenzas, SARS, AIDS, Ebola and smallpox viruses."

"This is an exciting development period for Viroblock and the most recent pre-clinical performance is a testament to our innovative and cutting-edge technology, the quality of our team, board of directors and investors."

"We, at Viroblock, leverage all our technological assets for rapidly developing the next generation of antiviral nasal sprays; I am also confident that our technology will become an important element of pandemic influenza preparedness efforts".

"Our ability to deliver tailored antiviral formulations, which can exist as colloidal suspensions, gels, creams, and aerosol sprays, opens promising business opportunities and a bright future for Viroblock.", comments CEO Thierry Pelet.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology.

Its patented VCCD technology allegedly inactivates all families and strains of enveloped viruses, like human and avian influenzas, RSV, SARS, AIDS, Ebola and smallpox viruses, and leverages a mechanism of action that limits the development of any viral resistance and toxicity. VCCD Tech products exist as colloidal suspensions, gels, creams, and aerosol sprays, having specific mechanical, physical and chemical properties

The W.A. De Vigier Foundation nominated Viroblock SA as one of the 10 best technology projects of the year 2006, and the Swiss Tech Tour 2007 Selection Committee has rated Viroblock SA as part of the top 50 technology companies in Switzerland.

Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

    Additional information is available on the company's website at
http://www.viroblock.com

    Contact:

    Thierry Pelet
    Chief Executive Officer
    Viroblock SA
    Phone: +41-22-884-83-44
    E-Mail: t.pelet@viroblock.com


'/>"/>
SOURCE Viroblock SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
2. IDM Pharma Reports 2008 Financial Results
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
4. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
5. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
7. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
9. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
10. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
11. Neogen Reports Record Third Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
Breaking Biology News(10 mins):